
Eric J. Mccullough
Examiner (ID: 10645, Phone: (571)272-8885 , Office: P/1773 )
| Most Active Art Unit | 1773 |
| Art Unit(s) | 1773, 1797 |
| Total Applications | 445 |
| Issued Applications | 114 |
| Pending Applications | 85 |
| Abandoned Applications | 269 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20402206
[patent_doc_number] => 12492174
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-09
[patent_title] => Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases
[patent_app_type] => utility
[patent_app_number] => 19/042986
[patent_app_country] => US
[patent_app_date] => 2025-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29739
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19042986
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/042986 | Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases | Jan 30, 2025 | Issued |
Array
(
[id] => 19940213
[patent_doc_number] => 12312335
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-05-27
[patent_title] => Crystalline pharmaceutically acceptable salt and polymorphic form of the glutaminyl cyclase inhibitor Varoglutamstat
[patent_app_type] => utility
[patent_app_number] => 19/020776
[patent_app_country] => US
[patent_app_date] => 2025-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 32
[patent_no_of_words] => 20260
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19020776
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/020776 | Crystalline pharmaceutically acceptable salt and polymorphic form of the glutaminyl cyclase inhibitor Varoglutamstat | Jan 13, 2025 | Issued |
Array
(
[id] => 19556293
[patent_doc_number] => 20240368085
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST
[patent_app_type] => utility
[patent_app_number] => 18/772244
[patent_app_country] => US
[patent_app_date] => 2024-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13439
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18772244
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/772244 | CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST | Jul 13, 2024 | Pending |
Array
(
[id] => 20213554
[patent_doc_number] => 12410196
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-09
[patent_title] => Benzopyrimidine compounds and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/768367
[patent_app_country] => US
[patent_app_date] => 2024-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38506
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18768367
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/768367 | Benzopyrimidine compounds and use thereof | Jul 9, 2024 | Issued |
Array
(
[id] => 20213554
[patent_doc_number] => 12410196
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-09
[patent_title] => Benzopyrimidine compounds and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/768367
[patent_app_country] => US
[patent_app_date] => 2024-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38506
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18768367
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/768367 | Benzopyrimidine compounds and use thereof | Jul 9, 2024 | Issued |
Array
(
[id] => 20213554
[patent_doc_number] => 12410196
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-09
[patent_title] => Benzopyrimidine compounds and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/768367
[patent_app_country] => US
[patent_app_date] => 2024-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38506
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18768367
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/768367 | Benzopyrimidine compounds and use thereof | Jul 9, 2024 | Issued |
Array
(
[id] => 19922913
[patent_doc_number] => 12297183
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => Heteroaryl azole compound and pest control agent
[patent_app_type] => utility
[patent_app_number] => 18/743634
[patent_app_country] => US
[patent_app_date] => 2024-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17107
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 389
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18743634
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/743634 | Heteroaryl azole compound and pest control agent | Jun 13, 2024 | Issued |
Array
(
[id] => 19922913
[patent_doc_number] => 12297183
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => Heteroaryl azole compound and pest control agent
[patent_app_type] => utility
[patent_app_number] => 18/743634
[patent_app_country] => US
[patent_app_date] => 2024-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17107
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 389
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18743634
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/743634 | Heteroaryl azole compound and pest control agent | Jun 13, 2024 | Issued |
Array
(
[id] => 19649983
[patent_doc_number] => 12171743
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-24
[patent_title] => Forms of aticaprant
[patent_app_type] => utility
[patent_app_number] => 18/679720
[patent_app_country] => US
[patent_app_date] => 2024-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 37
[patent_no_of_words] => 33621
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18679720
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/679720 | Forms of aticaprant | May 30, 2024 | Issued |
Array
(
[id] => 19701440
[patent_doc_number] => 12195449
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-14
[patent_title] => 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/650207
[patent_app_country] => US
[patent_app_date] => 2024-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35908
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650207
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/650207 | 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof | Apr 29, 2024 | Issued |
Array
(
[id] => 19343487
[patent_doc_number] => 20240252450
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => TREATMENT FOR EPILEPTIC SEIZURES
[patent_app_type] => utility
[patent_app_number] => 18/630615
[patent_app_country] => US
[patent_app_date] => 2024-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1956
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18630615
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/630615 | TREATMENT FOR EPILEPTIC SEIZURES | Apr 8, 2024 | Pending |
Array
(
[id] => 19536705
[patent_doc_number] => 12129246
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-10-29
[patent_title] => Hydroquinazoline derivatives for the treatment of a disease or disorder
[patent_app_type] => utility
[patent_app_number] => 18/589841
[patent_app_country] => US
[patent_app_date] => 2024-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41436
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 274
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18589841
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/589841 | Hydroquinazoline derivatives for the treatment of a disease or disorder | Feb 27, 2024 | Issued |
Array
(
[id] => 20127843
[patent_doc_number] => 12370143
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-29
[patent_title] => Compound or salt thereof and lipid particles
[patent_app_type] => utility
[patent_app_number] => 18/443959
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37474
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 401
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443959
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443959 | Compound or salt thereof and lipid particles | Feb 15, 2024 | Issued |
Array
(
[id] => 20127843
[patent_doc_number] => 12370143
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-29
[patent_title] => Compound or salt thereof and lipid particles
[patent_app_type] => utility
[patent_app_number] => 18/443959
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37474
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 401
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443959
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443959 | Compound or salt thereof and lipid particles | Feb 15, 2024 | Issued |
Array
(
[id] => 20127843
[patent_doc_number] => 12370143
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-29
[patent_title] => Compound or salt thereof and lipid particles
[patent_app_type] => utility
[patent_app_number] => 18/443959
[patent_app_country] => US
[patent_app_date] => 2024-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37474
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 401
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443959
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/443959 | Compound or salt thereof and lipid particles | Feb 15, 2024 | Issued |
Array
(
[id] => 20143904
[patent_doc_number] => 12378231
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-05
[patent_title] => Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/440166
[patent_app_country] => US
[patent_app_date] => 2024-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50957
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 424
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18440166
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/440166 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | Feb 12, 2024 | Issued |
Array
(
[id] => 19915173
[patent_doc_number] => 12290519
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-06
[patent_title] => Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/413842
[patent_app_country] => US
[patent_app_date] => 2024-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 40686
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18413842
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/413842 | Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof | Jan 15, 2024 | Issued |
Array
(
[id] => 19135569
[patent_doc_number] => 11970499
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-04-30
[patent_title] => Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/395130
[patent_app_country] => US
[patent_app_date] => 2023-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10287
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18395130
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/395130 | Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors | Dec 21, 2023 | Issued |
Array
(
[id] => 20014288
[patent_doc_number] => 20250152510
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-15
[patent_title] => LIPIDS AND LIPID NANOPARTICLE FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/532785
[patent_app_country] => US
[patent_app_date] => 2023-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22472
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 331
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18532785
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/532785 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS | Dec 6, 2023 | Pending |
Array
(
[id] => 19202754
[patent_doc_number] => 20240174653
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS
[patent_app_type] => utility
[patent_app_number] => 18/386267
[patent_app_country] => US
[patent_app_date] => 2023-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19243
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 194
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18386267
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/386267 | SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS | Nov 1, 2023 | Pending |